Insulin detemir
In clinical developmentAlso known as Detemir, Levemir, Insulina detemir, Insulin Detemir (Recombinant)+1 more
Detemir, Levemir, Insulina detemir, Insulin Detemir (Recombinant), Insulin detemir recombinant.
Recent clinical, regulatory, research and industry developments relating to this drug.
Making an "Obese"Brain(and Body)Lean: Insulin Detemir,Monoamines,and Reward
Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Diabetes, obesity & metabolism1
- Blonde L1
- Karwe V1
- Merilainen M1
- Raskin P1
- Ochsner Diabetes Clinical Research Unit1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials